{"id":40209,"date":"2025-08-27T13:14:16","date_gmt":"2025-08-27T05:14:16","guid":{"rendered":"https:\/\/flcube.com\/?p=40209"},"modified":"2025-08-27T13:14:17","modified_gmt":"2025-08-27T05:14:17","slug":"eisai-biogen-launch-lecanemab-in-austria-germany-first-cause%e2%80%91based-alzheimers-therapy","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=40209","title":{"rendered":"Eisai\u202f&amp;\u202fBiogen Launch Lecanemab in Austria &amp; Germany \u2013 First Cause\u2011Based Alzheimer\u2019s Therapy"},"content":{"rendered":"\n<p>Japan-based Eisai (<a href=\"https:\/\/www.google.com\/finance\/quote\/4523:TYO\">TYO: 4523<\/a>) and US-based Biogen (<a href=\"https:\/\/www.google.com\/finance\/quote\/BIIB:NASDAQ\">NASDAQ: BIIB<\/a>) have officially launched <strong>Lecanemab (LEQEMBI)<\/strong>\u2014the first anti\u2011amyloid \u03b2 monoclonal antibody approved by the European Commission (EC) for a <em>cause\u2011based<\/em> treatment of Alzheimer\u2019s disease (AD). The drug entered the Austrian market on <strong>25\u202fAugust,\u202f2025<\/strong> and will hit German pharmacies on <strong>1\u202fSeptember,\u202f2025<\/strong>.<\/p>\n\n\n\n<p><strong>Why Lecanemab Is a Milestone<\/strong><\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Feature<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Mechanism<\/strong><\/td><td>Targets soluble amyloid\u2011\u03b2 (A\u03b2) aggregates, slowing neurodegeneration<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Adults with mild cognitive impairment (MCI) or mild dementia <em>early AD<\/em>; requires ApoE\u202f\u03b54 non\u2011carrier or heterozygote status and confirmed amyloid pathology<\/td><\/tr><tr><td><strong>Regulatory status<\/strong><\/td><td>EC approval (April\u202f2025); first therapy to target underlying AD pathology in the EU<\/td><\/tr><tr><td><strong>Launch framework<\/strong><\/td><td>Controlled Access Program (CAP) in Austria &amp; Germany to ensure rapid, safe patient enrollment<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Commercial Arrangement<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Lead developer &amp; regulator<\/strong> \u2013 Eisai spearheads global submissions and holds Marketing Authorization Holder status in the EU (excluding the Nordic countries).<\/li>\n\n\n\n<li><strong>Co\u2011promotion<\/strong> \u2013 Eisai and Biogen jointly promote the product in the EU, with Eisai ultimately making the final business decisions.<\/li>\n\n\n\n<li><strong>Distribution<\/strong> \u2013 Eisai will distribute Lecanemab across the EU, leveraging its established supply chain.<\/li>\n<\/ul>\n\n\n\n<p><strong>Key Takeaways for Investors<\/strong><\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>Early\u2011AD market entry<\/strong> \u2013 Lecanemab addresses a growing unmet need for disease\u2011modifying therapy in early AD.<\/li>\n\n\n\n<li><strong>Strong regulatory footing<\/strong> \u2013 EC approval and the Controlled Access Program reduce market\u2011entry risk.<\/li>\n\n\n\n<li><strong>Strategic partnership<\/strong> \u2013 The Eisai\u2011Biogen alliance combines manufacturing expertise with a global commercial footprint, positioning the drug for rapid uptake in the EU.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"<p>Japan-based Eisai (TYO: 4523) and US-based Biogen (NASDAQ: BIIB) have officially launched Lecanemab (LEQEMBI)\u2014the first&#8230;<\/p>\n","protected":false},"author":1,"featured_media":40212,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[351,350,40,993,1151],"class_list":["post-40209","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-biogen","tag-eisai","tag-market-launch","tag-nasdaq-biib","tag-tyo-4523"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Eisai\u202f&amp;\u202fBiogen Launch Lecanemab in Austria &amp; Germany \u2013 First Cause\u2011Based Alzheimer\u2019s Therapy - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Eisai and Biogen have rolled out Lecanemab (lecanemab) in Austria (Aug\u202f25\u202f2025) and Germany (Sep\u202f1\u202f2025). Approved by the European Commission, the anti\u2011amyloid \u03b2 antibody treats early Alzheimer\u2019s in ApoE\u202f\u03b54 non\u2011carriers or heterozygotes. The launch is supported by a Controlled Access Program and joint commercialization led by Eisai.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=40209\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eisai\u202f&amp;\u202fBiogen Launch Lecanemab in Austria &amp; Germany \u2013 First Cause\u2011Based Alzheimer\u2019s Therapy\" \/>\n<meta property=\"og:description\" content=\"Eisai and Biogen have rolled out Lecanemab (lecanemab) in Austria (Aug\u202f25\u202f2025) and Germany (Sep\u202f1\u202f2025). Approved by the European Commission, the anti\u2011amyloid \u03b2 antibody treats early Alzheimer\u2019s in ApoE\u202f\u03b54 non\u2011carriers or heterozygotes. The launch is supported by a Controlled Access Program and joint commercialization led by Eisai.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=40209\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-27T05:14:16+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-08-27T05:14:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2701.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40209#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40209\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Eisai\u202f&amp;\u202fBiogen Launch Lecanemab in Austria &amp; Germany \u2013 First Cause\u2011Based Alzheimer\u2019s Therapy\",\"datePublished\":\"2025-08-27T05:14:16+00:00\",\"dateModified\":\"2025-08-27T05:14:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40209\"},\"wordCount\":252,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40209#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2701.webp\",\"keywords\":[\"Biogen\",\"Eisai\",\"Market launch\",\"NASDAQ: BIIB\",\"TYO: 4523\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=40209#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40209\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=40209\",\"name\":\"Eisai\u202f&amp;\u202fBiogen Launch Lecanemab in Austria &amp; Germany \u2013 First Cause\u2011Based Alzheimer\u2019s Therapy - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40209#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40209#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2701.webp\",\"datePublished\":\"2025-08-27T05:14:16+00:00\",\"dateModified\":\"2025-08-27T05:14:17+00:00\",\"description\":\"Eisai and Biogen have rolled out Lecanemab (lecanemab) in Austria (Aug\u202f25\u202f2025) and Germany (Sep\u202f1\u202f2025). Approved by the European Commission, the anti\u2011amyloid \u03b2 antibody treats early Alzheimer\u2019s in ApoE\u202f\u03b54 non\u2011carriers or heterozygotes. The launch is supported by a Controlled Access Program and joint commercialization led by Eisai.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40209#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=40209\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40209#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2701.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2701.webp\",\"width\":1080,\"height\":608,\"caption\":\"Eisai\u202f&\u202fBiogen Launch Lecanemab in Austria & Germany \u2013 First Cause\u2011Based Alzheimer\u2019s Therapy\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40209#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eisai\u202f&amp;\u202fBiogen Launch Lecanemab in Austria &amp; Germany \u2013 First Cause\u2011Based Alzheimer\u2019s Therapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Eisai\u202f&amp;\u202fBiogen Launch Lecanemab in Austria &amp; Germany \u2013 First Cause\u2011Based Alzheimer\u2019s Therapy - Insight, China&#039;s Pharmaceutical Industry","description":"Eisai and Biogen have rolled out Lecanemab (lecanemab) in Austria (Aug\u202f25\u202f2025) and Germany (Sep\u202f1\u202f2025). Approved by the European Commission, the anti\u2011amyloid \u03b2 antibody treats early Alzheimer\u2019s in ApoE\u202f\u03b54 non\u2011carriers or heterozygotes. The launch is supported by a Controlled Access Program and joint commercialization led by Eisai.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=40209","og_locale":"en_US","og_type":"article","og_title":"Eisai\u202f&amp;\u202fBiogen Launch Lecanemab in Austria &amp; Germany \u2013 First Cause\u2011Based Alzheimer\u2019s Therapy","og_description":"Eisai and Biogen have rolled out Lecanemab (lecanemab) in Austria (Aug\u202f25\u202f2025) and Germany (Sep\u202f1\u202f2025). Approved by the European Commission, the anti\u2011amyloid \u03b2 antibody treats early Alzheimer\u2019s in ApoE\u202f\u03b54 non\u2011carriers or heterozygotes. The launch is supported by a Controlled Access Program and joint commercialization led by Eisai.","og_url":"https:\/\/flcube.com\/?p=40209","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-08-27T05:14:16+00:00","article_modified_time":"2025-08-27T05:14:17+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2701.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=40209#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=40209"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Eisai\u202f&amp;\u202fBiogen Launch Lecanemab in Austria &amp; Germany \u2013 First Cause\u2011Based Alzheimer\u2019s Therapy","datePublished":"2025-08-27T05:14:16+00:00","dateModified":"2025-08-27T05:14:17+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=40209"},"wordCount":252,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=40209#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2701.webp","keywords":["Biogen","Eisai","Market launch","NASDAQ: BIIB","TYO: 4523"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=40209#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=40209","url":"https:\/\/flcube.com\/?p=40209","name":"Eisai\u202f&amp;\u202fBiogen Launch Lecanemab in Austria &amp; Germany \u2013 First Cause\u2011Based Alzheimer\u2019s Therapy - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=40209#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=40209#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2701.webp","datePublished":"2025-08-27T05:14:16+00:00","dateModified":"2025-08-27T05:14:17+00:00","description":"Eisai and Biogen have rolled out Lecanemab (lecanemab) in Austria (Aug\u202f25\u202f2025) and Germany (Sep\u202f1\u202f2025). Approved by the European Commission, the anti\u2011amyloid \u03b2 antibody treats early Alzheimer\u2019s in ApoE\u202f\u03b54 non\u2011carriers or heterozygotes. The launch is supported by a Controlled Access Program and joint commercialization led by Eisai.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=40209#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=40209"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=40209#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2701.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2701.webp","width":1080,"height":608,"caption":"Eisai\u202f&\u202fBiogen Launch Lecanemab in Austria & Germany \u2013 First Cause\u2011Based Alzheimer\u2019s Therapy"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=40209#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Eisai\u202f&amp;\u202fBiogen Launch Lecanemab in Austria &amp; Germany \u2013 First Cause\u2011Based Alzheimer\u2019s Therapy"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2701.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40209","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=40209"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40209\/revisions"}],"predecessor-version":[{"id":40213,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40209\/revisions\/40213"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/40212"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=40209"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=40209"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=40209"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}